You are here

ThromboGenics

Upcoming events – catalysts approach for Catalyst and Oxurion

EP Vantage

Fri, 07/19/19 - 07:27 pm

Catalyst Bioscences

More Good News for Bicycle Therapeutics

CP Wire

Sat, 05/26/18 - 09:37 am

Bicycle Therapeutics

vitreo-retinal disorders

ThromboGenics spins out Roche-rejected cancer drug

Fierce Biotech

Thu, 04/16/15 - 09:59 am

Thrombogenics swings to net loss as U.S. sales stall

Yahoo/Reuters

Fri, 03/13/15 - 08:44 am

ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales

Fierce Biotech

Mon, 09/1/14 - 10:52 am

Novartis to Shire Said to Weigh Bids for ThromboGenics

Bloomberg

Mon, 04/14/14 - 06:49 pm

Valeant Pharmaceuticals

ThromboGenics Plunges on Jetrea Sales Forecast

Bloomberg

Fri, 08/30/13 - 08:49 am

vitreomacular adhesion

ThromboGenics Bid Seen on Eye Drug Treatment: Real M&A

Bloomberg

Sat, 01/19/13 - 12:07 pm

ThromboGenics Bid Seen on Eye Drug Treatment: Real M&A

Bloomberg

Fri, 01/18/13 - 10:23 am

vitreomacular adhesion

Analysis: Maturing Belgian biotechs outshine European peers

Reuters

Thu, 10/4/12 - 10:48 am

With FDA panel nod, ThromboGenics closer to first potential drug

Fierce Biotech

Fri, 07/27/12 - 12:52 pm

vitreomacular adhesion

Thrombogenics CEO Discusses Product Pipeline Ahead of Catalysts, FDA Review

Yahoo/Reuters

Mon, 07/9/12 - 10:37 am

ThromboGenics Seeks Cash Deal on Clot Drug to Fund Microplasmin

Bloomberg

Fri, 11/5/10 - 11:22 am